TL;DR: Peptide Synthesis Starting with the N-Terminal Residue (N?C Strategy) and Side Reactions related to Individual Amino Acid Residues: Tactics and Strategy.
Abstract: I. Introduction.- References.- II. Activation and Coupling.- 1 Activation.- 2 Coupling.- 3 Coupling Methods.- 3.1 The Azide Procedure.- 3.2 Anhydrides.- 3.3 Active Esters.- 3.4 Coupling Reagents.- 3.5 Auxiliary Nucleophiles.- 3.6 Enzyme-Catalyzed Formation of the Peptide Bond.- 3.7 Comment on Various Coupling Methods.- References.- III. Reversible Blocking of Amino and Carboxyl Groups.- 1 General Aspects.- 1.1 The Need for Protecting Groups.- 1.2 Minimal Versus Global Protection.- 1.3 Easily Removable Protecting Groups and Methods Used for Their Removal.- 1.3.1 Reduction and Oxidation.- 1.3.2 Acidolysis - Carbocation Formation.- 1.3.3 Proton Abstraction (Carbanion Formation).- 1.3.4 Nucleophilic Displacement.- 1.3.5 Photolysis.- 1.3.6 Enzyme Catalyzed Hydrolysis.- 2 Protection of the Carboxyl Group.- 2.1 Benzyl Esters and Substituted Benzyl Esters.- 2.2 Methyl Esters and Substituted Methyl Esters.- 2.3 Ethyl Esters and Substituted Ethyl Esters.- 2.4 tert-Butyl Esters and Related Compounds.- 2.5 Aryl Esters.- 2.6 Hydrazides.- 3 Protection of the Amino Group.- 3.1 Alkyl and Alkylidene Protecting Groups.- 3.2 Protection by Acylation.- 3.3 Protection of the Amino Group in the Form of Urethanes.- 3.3.1 Urethane Type Protecting Groups.- 3.3.2 Introduction of Urethane Type Protecting Groups.- 3.3.3 Removal of Urethane-Type Protecting Groups.- 3.4 Protecting Groups Derived from Sulfur and Phosphorus.- References.- IV. Semipermanent Protection of Side Chain Functions.- 1 Carboxyl Groups of Aspartyl and Glutamyl Residues.- 2 Side Chain Amino Groups of Lysine and Ornithine.- 3 Hydroxyl Groups in Serine, Threonine and Tyrosine.- 4 The Sulfhydryl Group in Cysteine.- 5 The Guanidino Group of Arginine.- 6 Imidazole in Histidine.- 7 The Thioether in Methionine.- 8 The Indole Nitrogen in Tryptophan.- 9 The Carboxamide Groups in Asparagine and Glutamine.- References.- V. Side Reactions in Peptide Synthesis.- 1 Side Reactions Initiated by Proton Abstraction.- 1.1 Racemization.- 1.1.1 Mechanisms of Racemization.- 1.1.2 Models for the Study of Racemization.- 1.1.3 Detection of Racemization (Examination of Synthetic Peptides for the Presence of Unwanted Diastereoisomers).- 1.1.4 Conservation of Chiral Purity.- 1.2 Undesired Cyclization.- 1.3 O-Acylation.- 2 Side Reactions Initiated by Protonation.- 2.1 Racemization.- 2.2 Undesired Cyclization.- 2.3 Alkylation.- 2.4 Chain Fragmentation.- 3 Side Reactions Due to Overactivation.- 4 Side Reactions Related to Individual Amino Acid Residues.- References.- VI. Tactics and Strategy in Peptide Synthesis.- 1 Tactics.- 1.1 Combinations of Protecting Groups.- 1.2 Final Deprotection.- 2 Strategies.- 2.1 Segment Condensation.- 2.2 Stepwise Synthesis Starting with the N-Terminal Residue (N?C Strategy).- 2.3 Stepwise Synthesis Starting with the C-Terminal Residue (C?W Strategy).- 3 Disulfide Bridges.- 4 Synthesis of Cyclic Peptides.- 4.1 Homodetic Cyclopeptides.- 4.2 Heterodetic Cyclopeptides.- 5 Sequential Polypeptides.- 6 Partial Synthesis (Semisynthesis).- References.- VII. Techniques for the Facilitation of Peptide Synthesis.- 1 Solid Phase Peptide Synthesis (SPPS).- 1.1 The Insoluble Support.- 1.2 The Bond Between Peptide and Polymer.- 1.3 Protection and Deprotection.- 1.4 Methods of Coupling in SPPS.- 1.5 Separation of the Completed Peptide Chain from the Polymeric Support.- 1.6 Problems in Solid Phase Peptide Synthesis.- 2 Synthesis in Solution.- 2.1 Peptides Attached to Soluble Polymers.- 2.2 The "Handle" Method.- 2.3 Synthesis "in situ".- 2.4 Synthesis Without Isolation of Intermediates.- References.- VIII Recent Developments, New Trends.- 1 Formation of the Peptide Bond.- 1.1 Acid Chlorides and Fluorides.- 1.2 Anhydrides.- 13 Active Esters.- 1.4 Coupling Reagents.- 1.5 Non-Conventional Formation of the Peptide Bond.- 1.6 Enzyme-Catalyzed Formation of the Peptide Bond.- 1.7 Cyclization and Formation of Disulfide Bridges.- 2 Protecting Groups.- 2.1 Blocking of the Carboxyl Function.- 2.2 Amine Protecting Groups.- 2.3 Masking of Functional Groups in the Side Chains of Amino Acids.- 2.4 Methods for the Introduction and Removal of Protecting Groups.- 3 Solid Phase Peptide Synthesis.- 4 Undesired Reactions in Peptide Synthesis.- 5 New Trends and Perspectives.- References.
TL;DR: The mitochondrial benzodiazepine receptor has been solubilized with retention of reversible ligand binding, and the associated subunits were characterized, finding that VDAC and ADC, outer and inner mitochondrial membrane channel proteins, respectively, together with the 18-kDa subunit, may comprise mBzR at functionally important transport sites at the junction of two mitochondrial membranes.
Abstract: The mitochondrial benzodiazepine receptor (mBzR) has been solubilized with retention of reversible ligand binding, and the associated subunits were characterized. mBzR comprises immunologically distinct protein subunits of 18-, 30-, and 32-kDa. The 18-kDa protein is labeled by the isoquinoline carboxamide mBzR ligand [3H]PK14105, whereas the 30- and 32-kDa subunits are labeled by the benzodiazepine (Bz) ligands [3H]flunitrazepam and [3H]AHN-086. Selective antibodies and reagents identify the 32- and 30-kDa proteins as the voltage-dependent anion channel (VDAC) and the adenine nucleotide carrier (ADC), respectively. While isoquinoline carboxamide and Bz ligands target different subunits, they interact allosterically, as the binding of Bz and isoquinoline carboxamide ligands is mutually competitive at low nanomolar concentrations. Moreover, eosin-5-maleimide and mercuric chloride inhibit [3H]PK11195 binding to the intact receptor via sulfhydryl groups that are present in ADC. VDAC and ADC, outer and inner mitochondrial membrane channel proteins, respectively, together with the 18-kDa subunit, may comprise mBzR at functionally important transport sites at the junction of two mitochondrial membranes.
TL;DR: The carboxylic acid-pyridine supramolecular heterosynthon can be exploited to predictably generate binary crystalline phases involving rac-ibuprofen, rac-flurbiprofen or aspirin.
Abstract: The crystal engineering design strategy facilitates supramolecular synthesis of 13 new crystalline phases of carbamazepine (CBZ), an analgesic and anticonvulsant with known problems related to solubility and polymorphism. CBZ forms supramolecular complexes with the following molecules, all of which are complementary to CBZ in terms of hydrogen bonding and can therefore act as cocrystal formers: acetone (1a); DMSO (1b); benzoquinone (1c); terephthalaldehyde (1d); saccharin (1e); nicotinamide (1f); acetic acid (1g); formic acid (1h); butyric acid (1i); trimesic acid (1j); 5-nitroisophthalic acid (1k); adamantane-1,3,5,7-tetracarboxylic acid (1l); and formamide (1m). Two distinct strategies based upon selection of complementary hydrogen-bond functionalities and previously known supramolecular synthons were utilized: strategy I exploits the exofunctional nature of the carboxamide dimer as either a hydrogen-bond donor or a hydrogen-bond acceptor and thereby retains the carboxamide dimer that is present in al...